In the DFS panel (Figure 4D,F), results were similar to the OS analyses—higher MAOB expression, higher T stage, and a positive M stage independently and significantly affected survival periods of CRC patients (HR = 1.9, 3.26, and 4.93, 95% CI = 1.26–2.85, 1.42–7.43, and 3.14–7.72, p = 0.002, 0.005, and < 0.001 for the univariate analysis; HR = 1.78, 2.44, and 4.45, 95% CI = 1.15–2.74, 1.05–5.67, and 2.81–7.05, p = 0.009, 0.039, and <0.001 for the multivariate analysis, respectively). Here, MAOB is linked to colorectal carcinoma.